Spike Protein News and Research

RSS

Long COVID linked to persistence of SARS-CoV-2 spike protein in blood

A new study reports SARS-CoV-2 spike antigen and cytokine levels in a sample of infected individuals, of which a subset had long COVID.

11 Sep 2022

All SARS-CoV-2 variants neutralized by a potent new antibody

Researchers describe a mouse model used to generate a VH1-2 heavy chain (HC)- and Vκ1-33 light chain (LC)-based recombinant antibody that broadly neutralized all severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, including the newly emergent Omicron sub-variant BA.5.

9 Sep 2022

Promising anti-cancer agent may also prevent SARS-CoV-2 from replication

Based on findings from a new study by a Johns Hopkins Medicine-led research team, an effective means of fighting SARS-CoV-2, the virus that causes COVID-19, may be possible that circumvents the problem of waning immunity often observed when current vaccines deal with emerging COVID variants.

8 Sep 2022

Biosynthetic proteins show promise as SARS-CoV-2 antivirals targeting spike protein

Researchers developed an αRep series specific to the RBD of the SARS-CoV-2 S, which could easily adapt to work stably against SARS-CoV-2 variants at a low cost.

8 Sep 2022

The role of some important antioxidants in major clinical outcomes of subjects with COVID-19

Researchers investigated the role of antioxidants such as selenium, zinc, α-lipoic acid, and vitamins A, E, D, and C in improving the clinical outcomes of COVID-19.

8 Sep 2022

How does SARS-CoV-2 infection and vaccination impact human immune memory?

Researchers review current knowledge regarding the generation of immune memory responses and their durability post-infection and vaccination.

7 Sep 2022

First nasal vaccine for COVID-19 approved in India for emergency use

The world's first nasal vaccine for COVID-19 was approved Tuesday, Sept. 6, in India for emergency use. The vaccine, called iNCOVACC, is based on technology licensed from Washington University in St. Louis and developed in collaboration with Bharat Biotech International Limited in India.

7 Sep 2022

Plant production of nanobodies that neutralize the interaction between ACE2 receptor and SARS-CoV-2 spike protein

Researchers demonstrated the production of nanobodies against SARS-CoV-2 spike protein.

7 Sep 2022

Photocatalyst-based ViraMap platform maps SARS-CoV-2 spike protein interactions on the cell surface

Researchers performed the photocatalytic mapping of the SARS-CoV-2 spike protein-host cell membrane interactions.

7 Sep 2022

Researchers identify novel neutralizing monoclonal antibodies against SARS-CoV-2 in vaccinated individuals after wildtype infection

Researchers identified monoclonal antibodies that neutralize SARS-CoV-2 variants.

7 Sep 2022

Researchers develop universally accessible application that can simulate complex molecular interactions

A team led by University of Minnesota Twin Cities biomedical engineers has developed a universally accessible application that can simulate complex molecular interactions, which will allow researchers to design better treatments for diseases like cancer and COVID-19.

6 Sep 2022

Study suggests entry of SARS-CoV-2 requires an acidic pH

Researchers carried out real-time single-virion tracking in three dimensions to study the mechanisms and requirements of membrane attachment and fusion of SARS-CoV-2 with the host cell.

6 Sep 2022

How does ACE2 expression in target cells affect neutralization by antibodies to different spike epitopes?

Researchers evaluated how ACE2 expression in target cells impacts neutralization.

2 Sep 2022

The effects of SARS-CoV-2 infection on antibody and B-cell responses to a third dose of mRNA vaccination

Researchers assessed the impact of COVID-19 infection on B-cell and antibody responses to COVID-19 booster vaccination.

2 Sep 2022

The dynamics of neutralizing antibodies in a cohort of children and adolescents after SARS-CoV-2 infection

In a recent JAMA Pediatrics study, scientists analyzed a cohort containing children and adolescents after recovering from COVID-19 to determine the dynamics of neutralizing antibodies.

2 Sep 2022

A rapid and efficient method of identifying neutralizing nanobodies directed against SARS-CoV-2

A recent PLoS ONE study detected neutralizing nanobodies against SARS-CoV-2 from nanobody phage display libraries and via in vitro and ex vivo high-throughput screenings.

2 Sep 2022

New substance boosts the effect of protein-based COVID-19 vaccines

Ironically, some vaccines need their own "boosters." Adding an ingredient called an adjuvant can help vaccines elicit a more robust immune response, better training the body to fight a pathogen.

1 Sep 2022

Intranasally delivered neutralizing antibody protects against SARS-CoV-2 Omicron and Delta variants

The current study focused on the ability of this nmAb to neutralize Delta, Omicron, and other VOCs, as well as its efficacy when given by the intranasal route in an animal model.

1 Sep 2022

N501Y mutation and SARS-CoV-2 spike protein-angiotensin-converting enzyme-2 binding

In a new study, researchers assessed the effects of N501Y mutation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein on binding to angiotensin-converting enzyme-2 (ACE-2).

1 Sep 2022

What lessons can we learn from the COVID-19 pandemic for HIV?

A new study discussed how experiences from the coronavirus disease 2019 (COVID-19) pandemic could be leveraged for human immunodeficiency virus (HIV).

31 Aug 2022

Spike Protein News and Research

Long COVID linked to persistence of SARS-CoV-2 spike protein in blood

All SARS-CoV-2 variants neutralized by a potent new antibody

Promising anti-cancer agent may also prevent SARS-CoV-2 from replication

Biosynthetic proteins show promise as SARS-CoV-2 antivirals targeting spike protein

The role of some important antioxidants in major clinical outcomes of subjects with COVID-19

How does SARS-CoV-2 infection and vaccination impact human immune memory?

First nasal vaccine for COVID-19 approved in India for emergency use

Plant production of nanobodies that neutralize the interaction between ACE2 receptor and SARS-CoV-2 spike protein

Photocatalyst-based ViraMap platform maps SARS-CoV-2 spike protein interactions on the cell surface

Researchers identify novel neutralizing monoclonal antibodies against SARS-CoV-2 in vaccinated individuals after wildtype infection

Researchers develop universally accessible application that can simulate complex molecular interactions

Study suggests entry of SARS-CoV-2 requires an acidic pH

How does ACE2 expression in target cells affect neutralization by antibodies to different spike epitopes?

The effects of SARS-CoV-2 infection on antibody and B-cell responses to a third dose of mRNA vaccination

The dynamics of neutralizing antibodies in a cohort of children and adolescents after SARS-CoV-2 infection

A rapid and efficient method of identifying neutralizing nanobodies directed against SARS-CoV-2

New substance boosts the effect of protein-based COVID-19 vaccines

Intranasally delivered neutralizing antibody protects against SARS-CoV-2 Omicron and Delta variants

N501Y mutation and SARS-CoV-2 spike protein-angiotensin-converting enzyme-2 binding

What lessons can we learn from the COVID-19 pandemic for HIV?

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News